Adverum Biotechnologies (formerly known as Avalanche Biotechnologies) is a clinical-stage gene therapy company targeting unmet medical need in ophthalmology and rare diseases. It develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company is leveraging its next-generation adeno-associated virus (AAV)-based directed evolution platform to engineer AAV capsids with enhanced tropism for certain tissues and improved antibody neutralization profiles over existing AAV variants.